Symptoms and General Pathology

All Conditions

Neoplasms

Recurrence

Head and Neck Neoplasms

Disease Attributes

Antineoplastic Agents

All Drugs and Chemicals

Cetuximab

Cisplatin

Taxane

All patients are treated with Cabazitaxel.

25 mg/m2 every 3 weeks by IV administration

Cabazitaxel

This is a multi-center phase II study assessing whether cabazitaxel could be efficient for treatment of recurrent or metastatic head and neck cancer after failure of cisplatin, cetuximab and taxanes.

Patients will be treated with intravenous cabazitaxel 25 mg/m2 every 3 weeks (D1=D22) for 6 cycles.

In absence of progression disease or unacceptable toxicity, the treatment could be continued until a maximum of 10 cycles.

Disease response will be assessed every 6 weeks (i.e. every 2 cycles) clinically and by CT-scan.

An interim analysis will be carried out after the inclusion of the first 10 eligible and assessable patients.

A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes

A PHASE II, OPEN-LABEL, MULTICENTER TRIAL OF CABAZITAXEL IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER AFTER FAILURE OF CISPLATIN, CETUXIMAB AND TAXANES.

IPD will not be shared at an individual level, those data will be part of the study database including all enrolled patients.

To assess the efficacy of cabazitaxel in terms of non-progression at 6 weeks for the treatment of recurrent or metastatic head and neck cancer after failure of cisplatin, cetuximab and taxanes.

Non-progression will be assessed after centralized review of CT-scans.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes	NCT01620242	Recurrent Head ... Metastatic Head...	Cabazitaxel	18 Years -	UNICANCER
A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes	NCT01620242	Recurrent Head ... Metastatic Head...	Cabazitaxel	18 Years -	UNICANCER

Spots Global Cancer Trial Database for recurrent or metastatic head and neck cancer